Table 3.
Association of HIV/HCV viral markers and medication regimens with pASP (mmHg).
| β-estimate (mmHg) [95% CI]* |
p value | |
|---|---|---|
| Variables among All HIV + | ||
| HCV positive status | 1.47 [0.26, 2.67] | 0.0170 |
| HIV viral load (10,000 copies/mL) | − 0.02 [− 0.05, 0.02] | 0.3481 |
| CD4 + T-cell count (200 cells/mm3) | − 0.68 [− 1.10, − 0.27] | 0.0011 |
| ART regimen | ||
| NRTI + PI vs. No ART | 0.65 [− 1.28, 2.59] | 0.5088 |
| NRTI + NNRTI vs. No ART | 0.53 [− 1.59, 2.65] | 0.6258 |
| Other ART vs. No ART | − 0.90 [− 2.59, 0.79] | 0.2981 |
| Variables among All HCV cases | ||
| HIV positive status | 0.53 [− 0.99, 2.05] | 0.4922 |
| HCV viral load (10,000 copies/mL) | 0.001 [− 0.0003, 0.003] | 0.1084 |
| Interferon exposure | 0.70 [− 3.74, 5.13] | 0.7578 |
HCV hepatitis C virus, PASP pulmonary artery systolic pressure, CI confidence interval, ART anti-retroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor.
*Adjusted for: age, sex, race/ethnicity, and heart failure.